Laddar populära aktier...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFR...
Phase Holographic Imaging genomför just nu en företrädesemission om cirka 64 Mkr.
Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB (“PHI” or the “Company”) has notified the Company that he, toge...
Emissionsaktuella Phase Holographic genomför just nu en fullt ut garanterad företrädesemission om cirka 64 Mkr för att öka sin globala försä...
The subscription period in Phase Holographic Imaging PHI AB’s ("PHI" or the "Company") fully secured rights issue, totalling SEK 64.
Phase Holographic Imaging genomför just nu en fullt ut garanterad företrädesemission om cirka 64 Mkr som avslutas den 20 december.
Aktieägarna i Phase Holographic Imaging PHI AB (publ), (”Bolaget”), org.
The shareholders of Phase Holographic Imaging PHI AB (publ), (“the Company”), reg.
Phase Holographic Imaging genomför just nu en fullt ut garanterad företrädesemission om cirka 64 Mkr och vars teckningsperiod avslutas den 2...
PHI specializes in non-invasive cell analysis, enabling researchers to study cells without disrupting their natural state.
Idag, den 2 december 2024, hölls extra bolagsstämma i Phase Holographic Imaging PHI AB (publ), 556542-7811 (“Bolaget”).
Today, 2 December 2024, an Extraordinary General Meeting was held in Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”).
Phase Holographic Imaging PHI AB ("PHI" or the "Company") today announces that the Company’s global distributor Altium SA (“Altium”) has pla...
Interim Report 2, 2024/2025
Phase Holographic Imaging PHI AB (publ) hereby announces that the Board of Directors has decided to bring forward the company's report for Q...
Phase Holographic Imaging PHI AB (publ), 556542-7811 (“Bolaget”) håller extra bolagsstämma den 2 december 2024 kl.
Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an Extraordinary General Meeting on 2 December 2024 at 15.
Rättelse: Pressmeddelandet från 2024-10-29 med bolagets årsredovisning innehöll en felaktig version av årsredovisningen samt saknade revisio...
PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding electio...
Anders Månsson was recently appointed CEO of Phase Holographic Imaging.
Phase Holographic Imaging PHI AB (publ), reg.no 556542-7811 (the “Company”) held its annual general meeting on 31 October 2024.
Årsredovisning 2023/24
Phase Holographic Imaging PHI AB ("PHI") announces that the Company has been provided a loan of SEK 7 million from the main shareholder Alti...
Phase Holographic Imaging PHI AB ("PHI" or "Company") today announces that the new shares from the exercise of warrants of series TO 4 have ...
The board of Phase Holographic Imaging (PHI) has today appointed Anders Månsson as the new CEO of PHI as of November 1, 2024.
On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s ...
Phase Holographic Imaging recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional compone...
The shareholders of Phase Holographic Imaging PHI AB (publ), reg.
Aktieägarna i Phase Holographic Imaging PHI AB (publ), org.
The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imagin...
Phase Holographic Imaging (PHI) is excited to announce a significant order agreement from Altium for 20 HoloMonitor systems, which will be s...
Interim Report 1 2024/25
Today is the first day for the exercise of Phase Holographic Imaging PHI AB's ("PHI" or "Company") warrants of series TO 4 ("TO 4") which we...
Phase Holographic Imaging PHI AB ("PHI" or "the Company") hereby announces that the exercise price for the warrants of series TO 4 (”TO 4”),...
Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company”) held an extraordinary general meeting on 2 September 2024.
Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market.
Phase Holographic Imaging (PHI) is thrilled to announce its official approval for listing on the OTCQB Venture Market in the U.
Phase Holographic Imaging PHI AB (publ), reg. no. 556542-7811 (the "Company"), will hold an extraordinary general meeting on 2 September at ...
Phase Holographic PHI Imaging AB (publ), org. nr. 556542-7811 (”Bolaget”), håller extra bolagsstämma den 2 september 2024 kl.
PHI postpones the extraordinary general meeting until September 2, 2024
Phase Holographic PHI Imaging AB (publ), org. nr. 556542-7811 (”Bolaget”), håller extra bolagsstämma den 19 augusti 2024 kl.
Phase Holographic Imaging PHI AB (publ), reg. no. 556542-7811 (the "Company"), will hold an extraordinary general meeting on 19 August at 14...
Phase Holographic Imaging (PHI), announces the resignation of esteemed board member Leland Foster.
Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the ra...
Phase Holographic Imaging (PHI) is pursuing a dual listing on the US-based OTCQB Venture Market (“OTCQB”) to provide US-based investors with...
Year-end report 2023/24
Phase Holographic Imaging has entered into a partnership with the University College London, the first partnership in a hospital setting to ...
Phase Holographic Imaging (PHI) is pleased to announce a new distribution agreement between its global distribution partner, Altium, and Kem...
Phase Holographic Imaging (PHI) is pleased to announce a strategic expansion into the Spanish and Portuguese markets, facilitated by a new s...
Phase Holographic Imaging (PHI) is excited to announce a strategic partnership with University College London (UCL).
Phase Holographic Imaging (PHI) today announces that the Company has terminated the liquidity provider agreement with Pareto Securities AB.
Medtech company Phase Holographic Imaging recently secured a loan facility of SEK 7 million.
Phase Holographic Imaging PHI AB ("PHI" or the "Company") announces that the Company has secured a loan facility of in total SEK 7 million f...
Phase Holographic Imaging (PHI) is pleased to announce a strategic activity schedule for spring 2024, during which PHI will participate in s...
Interim Report 3 2023/24
With a sharp focus on expanding its market to regenerative medicine, medtech company PHI has a growth trajectory that is on a notable upward...
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging (PHI) is pleased to present a comprehensive opinion piece detailing the versatility and potential the Company sees...
Phase Holographic Imaging (PHI) is conveying the news that its global distributor, Altium S.
Phase Holographic Imaging PHI AB (publ), 556542–7811 (”Bolaget”) håller extra bolagsstämma den 14 mars 2024 kl.
Phase Holographic Imaging PHI AB (publ), 556542-7811 (the "Company") will hold an extraordinary general meeting on 14 March 2024 at 10.
A year ago, Patrik Eschricht assumed the role of CEO at PHI, heralding the shift towards regenerative medicine and a commitment to enhancing...
Phase Holographic Imaging (PHI) announces its participation in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, Februar...
Phase Holographic Imaging (PHI) is excited to announce that preliminary Q3 net sales are summing up to approximately 5MSEK.
Interim Report 2 2023/24
Phase Holographic Imaging (PHI) has appointed Pareto Securities as the Company’s liquidity provider.
Phase Holographic Imaging (PHI) announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office...
Phase Holographic Imaging PHI AB (“PHI” or “the Company”) Board of Directors’ proposal on a directed issue to Altium S.
Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company”) held an extraordinary general meeting on November 15, 2023.
Medtech company PHI has experienced a dynamic year, with multiple significant advancements resulting in a 230 per cent surge in the company’...
PHI’s largest investor, Altium S.A., has intensified its support for the company with a directed share issue of 9.
Korrigeringen härrör sig till fel veckodag för extra bolagsstämman vid tidigare publicering.
Phase Holographic Imaging PHI AB (publ) held its annual general meeting on the 27th of October 2023.
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542–7811 (”Bolaget”), kallas härmed till extra bolagsstämma tisdagen den 15 novemb...
Phase Holographic Imaging (PHI) informs the market that PHI’s largest investor, Altium S.
Phase Holographic Imaging (PHI) informs the market that PHI’s Board of Directors decided to propose signing Altium S.
Phase Holographic Imaging (PHI) informs the market that to raise capital, PHI’s Board of Directors proposes a direct issue of 2 374 820 new ...
Phase Holographic Imaging (PHI) proudly stands behind the Wake Forest Institute for Regenerative Medicine (WFIRM) as they contend as a final...
Styrelsen och verkställande direktören för Phase Holographic Imaging PHI AB (publ), organisationsnummer 556542-7811 och med säte i Lund, avg...
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542–7811, kallas härmed till årsstämma fredagen den 27 oktober 2023 kl.
The shareholders of Phase Holographic Imaging PHI AB (publ), 556542-7811, are hereby invited to the annual general meeting on Friday 27 Octo...
Interim Report 1 2023/24
Notice that Interim Report 1 2023/24 will be published on September 20, 2023
The board of Phase Holographic Imaging (PHI) AB has decided to move the company’s annual general meeting from 12 October 2023 to 27 October ...
In 2023, Phase Holographic Imaging has solidified its footprint in regenerative medicine.
Phase Holographic Imaging (PHI) becomes a member of the leading international advocacy organization Alliance for Regenerative Medicine (ARM)...
Swedish medtech company PHI released its year-end report last week, outlining its transformative phase and strategic focus on regenerative m...
Phase Holographic Imaging AB (PHI) announces today that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies.
During the early summer, medical technology company PHI embarked on a global tour to showcase their latest HoloMonitor products, lab instrum...
Year-end Report 2022/23
Phase Holographic Imaging changes the date for publication of Interim Report 4 2022/23 to June 26, 2023.
Phase Holographic Imaging (PHI) introduces the HoloMonitor M4FL system to the global scientific community at two major scientific conference...
Phase Holographic Imaging PHI AB (“PHI” or the “Company”) today announces that the new shares from the exercise of warrants of series TO 3 h...
Phase Holographic Imaging PHI AB (publ) höll den 9 maj 2023 extra bolagsstämma.
Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on 9 May 2023.
On 2 May 2023, the exercise period for warrants of series TO 3 (“TO 3”), which were issued in connection with Phase Holographic Imaging PHI ...
